Skip to main content

Advertisement

SpringerLink
Log in

The interplay between innate and adaptive immunity regulates cancer development

  • Symposium Paper
  • Published:
Cancer Immunology, Immunotherapy Aims and scope Submit manuscript

Abstract

There is increasing clinical and experimental evidence that inflammation and cancer are causally linked. Much progress has been made in understanding how inflammatory cells contribute to cancer development; however, it is still largely unknown which molecular mechanisms are responsible for initiation and maintenance of chronic inflammation associated with developing neoplasms. This review will discuss how the adaptive and innate immune systems interact during physiological and chronic inflammation, with a focus on studies revealing new insights into the role of adaptive immune cells as important regulators of chronic inflammation-associated carcinogenesis. We will speculate on whether current knowledge about the dysregulated interplay between adaptive and innate immunity during chronic inflammatory disorders might be useful in understanding and targeting the underlying mechanisms of chronic inflammation-associated neoplastic progression.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

Similar content being viewed by others

References

  1. Hanahan D, Weinberg RA (2000) The hallmarks of cancer. Cell 100:57

    CAS  PubMed  Google Scholar 

  2. Coussens LM, Werb Z (2002) Inflammation and cancer. Nature 420:860

    Article  CAS  PubMed  Google Scholar 

  3. Coussens LM, Raymond WW, Bergers G, Laig-Webster M, Behrendtsen O, Werb Z, Caughey GH, Hanahan D (1999) Inflammatory mast cells up-regulate angiogenesis during squamous epithelial carcinogenesis. Genes Dev 13:1382

    CAS  PubMed  Google Scholar 

  4. Coussens LM, Tinkle CL, Hanahan D, Werb Z (2000) MMP-9 supplied by bone marrow-derived cells contributes to skin carcinogenesis. Cell 103:481

    Article  CAS  PubMed  Google Scholar 

  5. Greten FR, Eckmann L, Greten TF, Park JM, Li ZW, Egan LJ, Kagnoff MF, Karin M (2004) IKKbeta links inflammation and tumorigenesis in a mouse model of colitis-associated cancer. Cell 118:285

    Article  CAS  PubMed  Google Scholar 

  6. Hiratsuka S, Nakamura K, Iwai S, Murakami M, Itoh T, Kijima H, Shipley JM, Senior RM, Shibuya M (2002) MMP9 induction by vascular endothelial growth factor receptor-1 is involved in lung-specific metastasis. Cancer Cell 2:289

    Article  CAS  PubMed  Google Scholar 

  7. Pikarsky E, Porat RM, Stein I, Abramovitch R, Amit S, Kasem S, Gutkovich-Pyest E, Urieli-Shoval S, Galun E, Ben-Neriah Y (2004) NF-kappaB functions as a tumour promoter in inflammation-associated cancer. Nature 431:461

    Article  CAS  PubMed  Google Scholar 

  8. Yang L, Debusk LM, Fukuda K, Fingleton B, Green-Jarvis B, Shyr Y, Matrisian LM, Carbone DP, Lin PC (2004) Expansion of myeloid immune suppressor Gr+CD11b+ cells in tumor-bearing host directly promotes tumor angiogenesis. Cancer Cell 6:409

    Article  CAS  PubMed  Google Scholar 

  9. Gorman C, Leandro M, Isenberg D (2003) B cell depletion in autoimmune disease. Arthritis Res Ther 5 (Suppl 4):S17

    Article  PubMed  Google Scholar 

  10. Ji H, Ohmura K, Mahmood U, Lee DM, Hofhuis FM, Boackle SA, Takahashi K, Holers VM, Walport M, Gerard C, Ezekowitz A, Carroll MC, Brenner M, Weissleder R, Verbeek JS, Duchatelle V, Degott C, Benoist C, Mathis D (2002) Arthritis critically dependent on innate immune system players. Immunity 16:157

    Article  CAS  PubMed  Google Scholar 

  11. Korganow AS, Ji H, Mangialaio S, Duchatelle V, Pelanda R, Martin T, Degott C, Kikutani H, Rajewsky K, Pasquali JL, Benoist C, Mathis D (1999) From systemic T cell self-reactivity to organ-specific autoimmune disease via immunoglobulins. Immunity 10:451

    Article  CAS  PubMed  Google Scholar 

  12. Liu Z, Diaz LA, Troy JL, Taylor AF, Emery DJ, Fairley JA, Giudice GJ (1993) A passive transfer model of the organ-specific autoimmune disease, bullous pemphigoid, using antibodies generated against the hemidesmosomal antigen, BP180. J Clin Invest 92:2480

    CAS  PubMed  Google Scholar 

  13. Matsumoto I, Staub A, Benoist C, Mathis D (1999) Arthritis provoked by linked T and B cell recognition of a glycolytic enzyme. Science 286:1732

    Article  CAS  PubMed  Google Scholar 

  14. Trouw LA, Groeneveld TW, Seelen MA, Duijs JM, Bajema IM, Prins FA, Kishore U, Salant DJ, Verbeek JS, van Kooten C, Daha MR (2004) Anti-C1q autoantibodies deposit in glomeruli but are only pathogenic in combination with glomerular C1q-containing immune complexes. J Clin Invest 114:679

    Article  CAS  PubMed  Google Scholar 

  15. Akira S, Takeda K (2004) Toll-like receptor signalling. Nat Rev Immunol 4:499

    Article  CAS  PubMed  Google Scholar 

  16. Sahu A, Lambris JD (2001) Structure and biology of complement protein C3, a connecting link between innate and acquired immunity. Immunol Rev 180:35

    Article  CAS  PubMed  Google Scholar 

  17. Walport MJ (2001) Complement. First of two parts. N Engl J Med 344:1058

    Article  CAS  PubMed  Google Scholar 

  18. Walport MJ (2001) Complement. Second of two parts. N Engl J Med 344:1140

    Article  CAS  PubMed  Google Scholar 

  19. Belardelli F, Ferrantini M (2002) Cytokines as a link between innate and adaptive antitumor immunity. Trends Immunol 23:201

    Article  CAS  PubMed  Google Scholar 

  20. Carroll MC (2004) The complement system in regulation of adaptive immunity. Nat Immunol 5:981

    Article  CAS  PubMed  Google Scholar 

  21. Goldrath AW, Bevan MJ (1999) Selecting and maintaining a diverse T-cell repertoire. Nature 402:255

    Article  CAS  PubMed  Google Scholar 

  22. Tonegawa S (1983) Somatic generation of antibody diversity. Nature 302:575

    Article  CAS  PubMed  Google Scholar 

  23. McHeyzer-Williams MG (2003) B cells as effectors. Curr Opin Immunol 15:354

    Article  CAS  PubMed  Google Scholar 

  24. Janeway CA, Travers P, Walport M, Shlomchik M (2001) Immunobiology. Garland, New York

    Google Scholar 

  25. Sprent J, Surh CD (2002) T cell memory. Annu Rev Immunol 20:551

    Article  CAS  PubMed  Google Scholar 

  26. Dranoff G (2004) Cytokines in cancer pathogenesis and cancer therapy. Nat Rev Cancer 4:11

    Article  CAS  PubMed  Google Scholar 

  27. Granucci F, Zanoni I, Feau S, Ricciardi-Castagnoli P (2003) Dendritic cell regulation of immune responses: a new role for interleukin 2 at the intersection of innate and adaptive immunity. Embo J 22:2546

    Article  CAS  PubMed  Google Scholar 

  28. Ottenhoff TH, Kumararatne D, Casanova JL (1998) Novel human immunodeficiencies reveal the essential role of type-I cytokines in immunity to intracellular bacteria. Immunol Today 19:491

    Article  CAS  PubMed  Google Scholar 

  29. Mempel TR, Henrickson SE, Von Andrian UH (2004) T-cell priming by dendritic cells in lymph nodes occurs in three distinct phases. Nature 427:154

    Article  CAS  PubMed  Google Scholar 

  30. Foti M, Granucci F, Ricciardi-Castagnoli P (2004) A central role for tissue-resident dendritic cells in innate responses. Trends Immunol 25:650

    Article  CAS  PubMed  Google Scholar 

  31. Kroczek RA, Mages HW, Hutloff A (2004) Emerging paradigms of T-cell co-stimulation. Curr Opin Immunol 16:321

    Article  CAS  PubMed  Google Scholar 

  32. Alahlafi AM, Wordsworth P, Wojnarowska F (2004) The lupus band: do the autoantibodies target collagen VII? Br J Dermatol 150:504

    Article  CAS  PubMed  Google Scholar 

  33. Wipke BT, Wang Z, Nagengast W, Reichert DE, Allen PM (2004) Staging the initiation of autoantibody-induced arthritis: a critical role for immune complexes. J Immunol 172:7694

    CAS  PubMed  Google Scholar 

  34. Humbles AA, Lu B, Nilsson CA, Lilly C, Israel E, Fujiwara Y, Gerard NP, Gerard C (2000) A role for the C3a anaphylatoxin receptor in the effector phase of asthma. Nature 406:998

    Article  CAS  PubMed  Google Scholar 

  35. Liu Z, Giudice GJ, Swartz SJ, Fairley JA, Till GO, Troy JL, Diaz LA (1995) The role of complement in experimental bullous pemphigoid. J Clin Invest 95:1539

    CAS  PubMed  Google Scholar 

  36. Hogarth PM (2002) Fc receptors are major mediators of antibody based inflammation in autoimmunity. Curr Opin Immunol 14:798

    Article  CAS  PubMed  Google Scholar 

  37. Ravetch JV, Bolland S (2001) IgG Fc receptors. Annu Rev Immunol 19:275

    Article  CAS  PubMed  Google Scholar 

  38. Sylvestre DL, Ravetch JV (1996) A dominant role for mast cell Fc receptors in the Arthus reaction. Immunity 5:387

    Article  CAS  Google Scholar 

  39. Watanabe N, Akikusa B, Park SY, Ohno H, Fossati L, Vecchietti G, Gessner JE, Schmidt RE, Verbeek JS, Ryffel B, Iwamoto I, Izui S, Saito T (1999) Mast cells induce autoantibody-mediated vasculitis syndrome through tumor necrosis factor production upon triggering Fcgamma receptors. Blood 94:3855

    CAS  PubMed  Google Scholar 

  40. Clynes R, Dumitru C, Ravetch JV (1998) Uncoupling of immune complex formation and kidney damage in autoimmune glomerulonephritis. Science 279:1052

    Article  CAS  PubMed  Google Scholar 

  41. Edwards JC, Szczepanski L, Szechinski J, Filipowicz-Sosnowska A, Emery P, Close DR, Stevens RM, Shaw T (2004) Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis. N Engl J Med 350:2572

    Article  CAS  PubMed  Google Scholar 

  42. Stasi R, Pagano A, Stipa E, Amadori S (2001) Rituximab chimeric anti-CD20 monoclonal antibody treatment for adults with chronic idiopathic thrombocytopenic purpura. Blood 98:952

    Article  CAS  PubMed  Google Scholar 

  43. Quartier P, Brethon B, Philippet P, Landman-Parker J, Le Deist F, Fischer A (2001) Treatment of childhood autoimmune haemolytic anaemia with rituximab. Lancet 358:1511

    Article  CAS  PubMed  Google Scholar 

  44. Looney RJ, Anolik JH, Campbell D, Felgar RE, Young F, Arend LJ, Sloand JA, Rosenblatt J, Sanz I (2004) B cell depletion as a novel treatment for systemic lupus erythematosus: a phase I/II dose-escalation trial of rituximab. Arthritis Rheum 50:2580

    Article  CAS  PubMed  Google Scholar 

  45. Funada Y, Noguchi T, Kikuchi R, Takeno S, Uchida Y, Gabbert HE (2003) Prognostic significance of CD8+ T cell and macrophage peritumoral infiltration in colorectal cancer. Oncol Rep 10:309

    PubMed  Google Scholar 

  46. Nakakubo Y, Miyamoto M, Cho Y, Hida Y, Oshikiri T, Suzuoki M, Hiraoka K, Itoh T, Kondo S, Katoh H (2003) Clinical significance of immune cell infiltration within gallbladder cancer. Br J Cancer 89:1736

    Article  CAS  PubMed  Google Scholar 

  47. Oshikiri T, Miyamoto M, Shichinohe T, Suzuoki M, Hiraoka K, Nakakubo Y, Shinohara T, Itoh T, Kondo S, Katoh H (2003) Prognostic value of intratumoral CD8+ T lymphocyte in extrahepatic bile duct carcinoma as essential immune response. J Surg Oncol 84:224

    Article  PubMed  Google Scholar 

  48. Wakabayashi O, Yamazaki K, Oizumi S, Hommura F, Kinoshita I, Ogura S, Dosaka-Akita H, Nishimura M (2003) CD4(+) T cells in cancer stroma, not CD8(+) T cells in cancer cell nests, are associated with favorable prognosis in human non-small cell lung cancers. Cancer Sci 94:1003

    CAS  PubMed  Google Scholar 

  49. Benitez-Bribiesca L, Wong A, Utrera D, Castellanos E (2001) The role of mast cell tryptase in neoangiogenesis of premalignant and malignant lesions of the uterine cervix. J Histochem Cytochem 49:1061

    CAS  PubMed  Google Scholar 

  50. Bingle L, Brown NJ, Lewis CE (2002) The role of tumour-associated macrophages in tumour progression: implications for new anticancer therapies. J Pathol 196:254

    Article  CAS  PubMed  Google Scholar 

  51. Imada A, Shijubo N, Kojima H, Abe S (2000) Mast cells correlate with angiogenesis and poor outcome in stage I lung adenocarcinoma. Eur Respir J 15:1087

    Article  CAS  PubMed  Google Scholar 

  52. Lin EY, Pollard JW (2004) Macrophages: modulators of breast cancer progression. Novartis Found Symp 256:158

    CAS  PubMed  Google Scholar 

  53. Takanami I, Takeuchi K, Naruke M (2000) Mast cell density is associated with angiogenesis and poor prognosis in pulmonary adenocarcinoma. Cancer 88:2686

    Article  CAS  PubMed  Google Scholar 

  54. Shacter E, Weitzman SA (2002) Chronic inflammation and cancer. Oncology 16:217

    PubMed  Google Scholar 

  55. Clevers H (2004) At the crossroads of inflammation and cancer. Cell 118:671

    Article  CAS  PubMed  Google Scholar 

  56. Turini ME, DuBois RN (2002) Cyclooxygenase-2: a therapeutic target. Annu Rev Med 53:35

    Article  CAS  PubMed  Google Scholar 

  57. Balkwill F, Mantovani A (2001) Inflammation and cancer: back to Virchow? Lancet 357:539

    Article  CAS  PubMed  Google Scholar 

  58. Arbeit JM, Munger K, Howley PM, Hanahan D (1994) Progressive squamous epithelial neoplasia in K14-human papillomavirus type 16 transgenic mice. J Virol 68:4358

    CAS  PubMed  Google Scholar 

  59. Coussens LM, Hanahan D, Arbeit JM (1996) Genetic predisposition and parameters of malignant progression in K14- HPV16 transgenic mice. Am J Path 149:1899

    CAS  PubMed  Google Scholar 

  60. Lin EY, Nguyen AV, Russell RG, Pollard JW (2001) Colony-stimulating factor 1 promotes progression of mammary tumors to malignancy. J Exp Med 193:727

    Article  CAS  PubMed  Google Scholar 

  61. Sparmann A, Bar-Sagi D (2004) Ras-induced interleukin-8 expression plays a critical role in tumor growth and angiogenesis. Cancer Cell 6:447

    Article  CAS  PubMed  Google Scholar 

  62. Almand B, Clark JI, Nikitina E, van Beynen J, English NR, Knight SC, Carbone DP, Gabrilovich DI (2001) Increased production of immature myeloid cells in cancer patients: a mechanism of immunosuppression in cancer. J Immunol 166:678

    CAS  PubMed  Google Scholar 

  63. Serafini P, De Santo C, Marigo I, Cingarlini S, Dolcetti L, Gallina G, Zanovello P, Bronte V (2004) Derangement of immune responses by myeloid suppressor cells. Cancer Immunol Immunother 53:64

    Article  CAS  PubMed  Google Scholar 

  64. Kusmartsev S, Gabrilovich DI (2002) Immature myeloid cells and cancer-associated immune suppression. Cancer Immunol Immunother 51:293

    Article  CAS  PubMed  Google Scholar 

  65. Gabrilovich DI, Velders MP, Sotomayor EM, Kast WM (2001) Mechanism of immune dysfunction in cancer mediated by immature Gr-1+ myeloid cells. J Immunol 166:5398

    CAS  PubMed  Google Scholar 

  66. Balkwill F, Coussens LM (2004) Cancer: an inflammatory link. Nature 431:405

    Article  CAS  PubMed  Google Scholar 

  67. Barbera-Guillem E, Nyhus JK, Wolford CC, Friece CR, Sampsel JW (2002) Vascular endothelial growth factor secretion by tumor-infiltrating macrophages essentially supports tumor angiogenesis, and IgG immune complexes potentiate the process. Cancer Res 62:7042

    CAS  PubMed  Google Scholar 

  68. Esposito I, Menicagli M, Funel N, Bergmann F, Boggi U, Mosca F, Bevilacqua G, Campani D (2004) Inflammatory cells contribute to the generation of an angiogenic phenotype in pancreatic ductal adenocarcinoma. J Clin Pathol 57:630

    Article  CAS  PubMed  Google Scholar 

  69. Bergers G, Brekken R, McMahon G, Vu TH, Itoh T, Tamaki K, Tanzawa K, Thorpe P, Itohara S, Werb Z, Hanahan D (2000) Matrix metalloproteinase-9 triggers the angiogenic switch during carcinogenesis. Nat Cell Biol 2:737

    Article  CAS  PubMed  Google Scholar 

  70. de Visser KE, Coussens LM (2004) Inflammation and matrix metalloproteinases: implications for cancer development. In: Morgan DW, Forssmann UJ, Nakada MT (eds) Cancer and inflammation. Birkhauser, Basel, p 71

  71. Egeblad M, Werb Z (2002) New functions for the matrix metalloproteinases in cancer progression. Nat Rev Cancer 2:161

    Article  CAS  PubMed  Google Scholar 

  72. van Kempen LCL, Rhee JS, Dehne K, Lee J, Edwards DR, Coussens LM (2002) Epithelial carcinogenesis: dynamic interplay between neoplastic cells and their microenvironment. Differentiation 70:501

    Google Scholar 

  73. Dunn GP, Old LJ, Schreiber RD (2004) The immunobiology of cancer immunosurveillance and immunoediting. Immunity 21:137

    Article  CAS  PubMed  Google Scholar 

  74. Pardoll DM (2003) Does the immune system see tumors as foreign or self? Annu Rev Immunol 21:807

    Article  CAS  PubMed  Google Scholar 

  75. Boshoff C, Weiss R (2002) AIDS-related malignancies. Nat Rev Cancer 2:373

    Article  CAS  PubMed  Google Scholar 

  76. Birkeland SA, Storm HH, Lamm LU, Barlow L, Blohme I, Forsberg B, Eklund B, Fjeldborg O, Friedberg M, Frodin L et al (1995) Cancer risk after renal transplantation in the Nordic countries, 1964–1986. Int J Cancer 60:183

    CAS  PubMed  Google Scholar 

  77. Euvrard S, Kanitakis J, Claudy A (2003) Skin cancers after organ transplantation. N Engl J Med 348:1681

    Article  PubMed  Google Scholar 

  78. Penn I (1999) Posttransplant malignancies. Transplant Proc 31:1260

    Article  CAS  PubMed  Google Scholar 

  79. Pham SM, Kormos RL, Landreneau RJ, Kawai A, Gonzalez-Cancel I, Hardesty RL, Hattler BG, Griffith BP (1995) Solid tumors after heart transplantation: lethality of lung cancer. Ann Thorac Surg 60:1623

    Article  CAS  PubMed  Google Scholar 

  80. Fung JJ, Jain A, Kwak EJ, Kusne S, Dvorchik I, Eghtesad B (2001) De novo malignancies after liver transplantation: a major cause of late death. Liver Transpl 7:S109

    Article  CAS  PubMed  Google Scholar 

  81. Gallagher B, Wang Z, Schymura MJ, Kahn A, Fordyce EJ (2001) Cancer incidence in New York State acquired immunodeficiency syndrome patients. Am J Epidemiol 154:544

    Article  CAS  PubMed  Google Scholar 

  82. Stewart T, Tsai SC, Grayson H, Henderson R, Opelz G (1995) Incidence of de-novo breast cancer in women chronically immunosuppressed after organ transplantation. Lancet 346:796

    Article  CAS  PubMed  Google Scholar 

  83. Alaedini A, Green PH (2005) Narrative review: celiac disease: understanding a complex autoimmune disorder. Ann Intern Med 142:289

    PubMed  Google Scholar 

  84. Nived O, Bengtsson A, Jonsen A, Sturfelt G, Olsson H (2001) Malignancies during follow-up in an epidemiologically defined systemic lupus erythematosus inception cohort in southern Sweden. Lupus 10:500

    Article  CAS  PubMed  Google Scholar 

  85. Blumenfeld Z, Lorber M, Yoffe N, Scharf Y (1994) Systemic lupus erythematosus: predisposition for uterine cervical dysplasia. Lupus 3:59

    CAS  PubMed  Google Scholar 

  86. Artinian V, Kvale PA (2004) Cancer and interstitial lung disease. Curr Opin Pulm Med 10:425

    Article  PubMed  Google Scholar 

  87. Mellemkjaer L, Linet MS, Gridley G, Frisch M, Moller H, Olsen JH (1996) Rheumatoid arthritis and cancer risk. Eur J Cancer 32A:1753

    Article  Google Scholar 

  88. Thomas E, Brewster DH, Black RJ, Macfarlane GJ (2000) Risk of malignancy among patients with rheumatic conditions. Int J Cancer 88:497

    Article  CAS  PubMed  Google Scholar 

  89. Thomas E, Symmons DP, Brewster DH, Black RJ, Macfarlane GJ (2003) National study of cause-specific mortality in rheumatoid arthritis, juvenile chronic arthritis, and other rheumatic conditions: a 20 year followup study. J Rheumatol 30:958

    PubMed  Google Scholar 

  90. Cibere J, Sibley J, Haga M (1997) Rheumatoid arthritis and the risk of malignancy. Arthritis Rheum 40:1580

    CAS  PubMed  Google Scholar 

  91. Gridley G, McLaughlin JK, Ekbom A, Klareskog L, Adami HO, Hacker DG, Hoover R, Fraumeni JF Jr (1993) Incidence of cancer among patients with rheumatoid arthritis. J Natl Cancer Inst 85:307

    CAS  PubMed  Google Scholar 

  92. Agassy-Cahalon L, Yaakubowicz M, Witz IP, Smorodinsky NI (1988) The immune system during the precancer period: naturally-occurring tumor reactive monoclonal antibodies and urethane carcinogenesis. Immunol Lett 18:181

    Article  CAS  PubMed  Google Scholar 

  93. Kaliss N (1958) Immunological enhancement of tumor homografts in mice: a review. Cancer Res 18:992

    CAS  PubMed  Google Scholar 

  94. Snell GD (1957) Incompatibility reactions to tumor homotransplants with particular reference to the role of the tumor; a review. Cancer Res 17:2

    CAS  PubMed  Google Scholar 

  95. Brodt P, Gordon J (1982) Natural resistance mechanisms may play a role in protection against chemical carcinogenesis. Cancer Immunol Immunother 13:125

    Article  CAS  PubMed  Google Scholar 

  96. Monach PA, Schreiber H, Rowley DA (1993) CD4+ and B lymphocytes in transplantation immunity. II. Augmented rejection of tumor allografts by mice lacking B cells. Transplantation 55:1356

    CAS  PubMed  Google Scholar 

  97. Schreiber H, Wu TH, Nachman J, Rowley DA (2000) Immunological enhancement of primary tumor development and its prevention. Semin Cancer Biol 10:351

    Article  CAS  PubMed  Google Scholar 

  98. Siegel CT, Schreiber K, Meredith SC, Beck-Engeser GB, Lancki DW, Lazarski CA, Fu YX, Rowley DA, Schreiber H (2000) Enhanced growth of primary tumors in cancer-prone mice after immunization against the mutant region of an inherited oncoprotein. J Exp Med 191:1945

    Article  CAS  PubMed  Google Scholar 

  99. Barbera-Guillem E, May KF Jr, Nyhus JK, Nelson MB (1999) Promotion of tumor invasion by cooperation of granulocytes and macrophages activated by anti-tumor antibodies. Neoplasia 1:453

    Article  CAS  PubMed  Google Scholar 

  100. de Visser KE, Korets LV, Coussens LM (2004) Early neoplastic progression is complement independent. Neoplasia 6:768

    PubMed  Google Scholar 

  101. McLaughlin P, White CA, Grillo-Lopez AJ, Maloney DG (1998) Clinical status and optimal use of rituximab for B-cell lymphomas. Oncology (Huntingt) 12:1763

    CAS  Google Scholar 

  102. Bussel JB (2000) Fc receptor blockade and immune thrombocytopenic purpura. Semin Hematol 37:261

    Article  CAS  PubMed  Google Scholar 

  103. von Mehren M, Adams GP, Weiner LM (2003) Monoclonal antibody therapy for cancer. Annu Rev Med 54:343

    Article  PubMed  Google Scholar 

  104. de Visser KE, Korets LV, Coussens LM (2005) De novo carcinogenesis promoted by chronic inflammation is B lymphocyte-dependent. Cancer Cell in press

Download references

Acknowledgments

We gratefully acknowledge Drs. Alexandra Eichten and Stephen Robinson for valuable suggestions. KEdV is a fellow of the Dutch Cancer Society. LMC is supported by the National Cancer Institute, National Institute of Diabetes & Digestive & Kidney Diseases, Department of Army, Breast Cancer Center of Excellence and National Institutes of Health, Center for Proteolytic Pathways.

Author information

Authors and Affiliations

  1. Cancer Research Institute, University of California, San Francisco, 2340 Sutter St., N-261, San Francisco, CA, 94143

    K. E. de Visser & L. M. Coussens

  2. Department of Pathology, University of California, San Francisco, 2340 Sutter St., San Francisco, CA, 94143

    L. M. Coussens

  3. Comprehensive Cancer Center, University of California, San Francisco, 2340 Sutter St, San Francisco, CA, 94143

    L. M. Coussens

Authors
  1. K. E. de Visser
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. L. M. Coussens
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to K. E. de Visser.

Additional information

This article is a symposium paper from the conference “Tumor Escape and its Determinants”, held in Salzburg, Austria, on 10–13 October 2004

Rights and permissions

Reprints and permissions

About this article

Cite this article

de Visser, K.E., Coussens, L.M. The interplay between innate and adaptive immunity regulates cancer development. Cancer Immunol Immunother 54, 1143–1152 (2005). https://doi.org/10.1007/s00262-005-0702-5

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00262-005-0702-5

Keywords

Search

Navigation